Medcura (formerly gel-e Inc.), a privately held, clinical-stage medical device company, develops a broad range of hemostatic and wound treatment products, including bandages for the treatment of routine cuts and scrapes, foams and putties for traumatic and military injuries, and surgical gels and powders.

XChanger Companies, Inc. is the owner and implementation group for a patented product with a new strategy in heating and cooling. The XChanger technology involves efficiently stratifying air to decrease the amount of energy required to heat and cool a space. The company’s methodology is different from conventional HVAC techniques on the market today. XChanger has the ability to deliver conditioned air to targeted locations directly, dependent upon temperature and demand. Supplies and returns become free-flowing ducts, able to deliver or remove air as the system dictates. The XChanger is a complementary technology, working with any forced air system, including those powered by oil, gas, electric and geo-thermal. The system of air delivery requires only a minor modification to an existing unit, and can cleanly stack atop or below an existing unit.

Shore Thing Shellfish is a small, member-owned and operated oyster farm in St. Mary’s County dedicated to producing quality shellfish and providing oyster-based services.

Oyster larvae are free-swimming for most of their lives; however, once they reach maturity they “strike” onto hard substrates like hard oyster shells. Farmers growing oysters in the form of spat (baby oysters) on shell typically bag up oyster shells, load the shell bags into a setting tank, and once the larvae strike, unload the shell bags and transport them to the area where the oysters will grow to maturity. Not only is this remote setting method labor and time-intensive, but it also causes spat mortality due to transport.

Shore Thing Shellfish plans to commercialize an oyster ‘in-situ’ setting process, as opposed to traditional land-based remote setting. This method will provide an on-site, cost effective, and environmentally friendly alternative to remote setting methods for holders of lease bottoms.

MeTompkin Seafood is a seafood processing company specializing in soft shell crabs, crab meat and oysters. The company is led by the Todd family, which has been working at catching and selling seafood from the Chesapeake Bay for eight generations.

BSI designs, manufactures and installs industrial robotics, automation software, and smart sensors for the nuclear, industrial, pharmaceutical, and petroleum markets. One of the company’s primary products is the Eagle Array, an online, automated system used for monitoring corrosion/erosion on high-risk piping to help prevent pipeline failures. The multiple-sensor array is non-intrusive, easily installed and networked to a single Eagle Link gateway.

Vasoptic Medical Inc. is a medical device company developing and commercializing high-quality, cost-effective products for the non invasive, dynamic assessment of retinal blood flow and vascular status. Vasoptic Medical has developed a low-cost, portable, noninvasive retinal imaging instrument (the XyCAM), which can complement fundus photographs with retinal blood flow information obtained at high spatio-temporal resolution without the introduction of any dyes. This handheld retinal imager has the potential to help detect a number of clinical conditions, including diabetic retinopathy (DR), glaucoma, and age-related macular degeneration. Early detection can often prevent vision loss. The XyCAM device is being designed to detect these conditions inn their earliest stages to help healthcare providers manage and prevent DR and glaucoma progression through a convenient, low-cost, minimally invasive procedure.

HY-TEK Bio is an early stage company developing a patent-pending system to remove carbon dioxide and other harmful greenhouse gases from smoke stack flue gas using a unique strain of algae while producing valuable byproducts from the algae. The company’s system mitigates greenhouse gas from flue gases by injecting the flue gas into a tank full of a unique strain of algae. The tank is a patent-pending, closed bioreactor produced in-house from a lamination of Mylar and Kevlar. This patent-pending construct allows the bioreactors to be produced inexpensively while being extremely light weight. In addition, patent-pending LED Grow Lights are used along with a nutrient developed in-house, made from fresh chicken manure and a blend of other proprietary components.

The algae feeds on the CO2 and NOx in the flue gas, as well as on the nutrient. CO2 consumption is enhanced through the use of proprietary LED Grow Light technology, yielding minimal greenhouse gas emissions and high yields of high-value algal biomass. The process produces little to no CO2 or NOx emissions, while enhancing the lipid-oil production in the algae as well as a by-product of Lutein-Zeaxanthin, an ultra-antioxidant that is in high demand in the market place. The algal biomass can be sold to brokers, who place the biomass into markets that produce Lutein-Zeaxanthin-based products, bio-plastics, skin care products, cosmetic and paint thickeners, additives for human and animal food products, and biofuel.

SilcsBio started operations in April, 2013, based on licensed intellectual property developed by Alexander MacKerell. SilcsBio is commercializing analysis tools with novel software capabilities for drug design, which could lead to the discovery of new molecules with decreased development costs. SilcsBio’s first products are designed to improve the modeling of drug candidate-protein interactions.

CARE-2 has developed the CARE-2 Risk & Needs Assessment, a 57-item assessment form that measures the risk factors associated with youth violence, as well as protective factors. Areas covered include youth characteristics, peer relationships, school and education issues, family dynamics and protective factors. Clinicians can complete the assessment and score the form in 15-30 minutes. The scored assessment form is then used to complete the Case Management Planning Form. This form helps clinicians gauge the intensity of potential behavior problems and identify the appropriate level and types of interventions needed. CARE-2 is the only risk assessment tool to provide this added feature.

Otomagnetics, a University of Maryland College Park spin-out, is developing a noninvasive method to effectively deliver drugs and other therapeutic payloads to inner and middle ear compartments, to the eye, and into the skin.

The inner ear is behind the blood-labyrinth barrier. Vessels that supply blood to the inner ear have walls that are impermeable to most drug molecules, and thus it is a challenge to deliver therapy to treat inner ear diseases. In animal models, Otomagnetics’ proprietary magnetic injection system has demonstrated drug delivery to the inner ear. It has also shown improved dosing and therapeutic effect in preclinical models of tinnitus and noise-induced hearing loss, and prevented hearing loss due to chemotherapy regimens.

In animal models, Otomagnetics’ technology has further shown drug delivery to the middle ear, without the need to puncture the ear drum. Magnetic delivery to the middle ear is being considered as a potential non-invasive treatment option for otitis media (middle ear infections). Magnetic forces have also delivered therapy into the eye, without needles. Otomagnetics products are experimental, and not approved by the FDA for human use.

Information Technologies Curves, or IT Curves®, develops state-of-the-art transportation and logistics management software serving enterprises in over 30 cities in the U.S. IT Curves’ software allows enterprises to monitor and manage mobile resources (which operate outside of the office) with the same level of accuracy as inoffice staff and resources. IT Curves’ system allows enterprises such as taxi, limousine, shuttle, campus bus systems, trucking, and other logistics management enterprises to accurately monitor, assign tasks, verify completion of the task, and process payments for these resources while on the road. IT Curves uses standard, off-the-shelf cellular phones and tablets, wireless data communication, accurate GPS positioning, and built-in navigation to enable mobile resources to be managed as an integral part of the company at all times.

InstantLabs is a molecular diagnostic device company and the developer of portable, quantitative, real-time PCR (qPCR) systems. The company is focused on medical diagnostic and food safety applications for its proprietary technologies. InstantLabs currently markets its Hunter Accelerated-PCR® platform with disposable Multiple Assay Cartridges (MACs), bringing simplicity and power to complex diagnostic testing without dependency on central laboratories or acute-care facilities for sample analysis. The compact, affordable and fully-integrated Hunter system is especially suited for use at points-of-care and points-of-need to detect and analyze a wide variety of common and problematic pathogens. InstantLabs is positioned to broaden the addressable market for RT-PCR in areas where gold-standard accuracy, combined with ease-of-use and rapid time to results, can make a consequential improvement in operational efficiency, as well as health outcomes.